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Abstract
Background: Leukocyte cytosolic proteins (e.g., calpro-
tectin) are emerging biomarkers for inflammatory bowel 
disease. Leukocyte aryl esterase activity has been com-
monly used for sensitive detection of leukocytes in human 
body fluids such as urine. Urine test strip results are gen-
erally reported in categories. As automated strip readers 
allow quantitative data to be reported, sensitive quanti-
tative detection of leukocytes in body fluids has become 
possible. Here, we explored the use of leukocyte esterase 
as a potential alternative faecal biomarker for inflamma-
tory bowel disease.
Methods: We evaluated leukocyte esterase activity in 
faecal extracts and compared Cobas u 411 (Roche) quan-
titative reflectance data with calprotectin concentration 
for 107 routine samples. Stability of leukocyte esterase for 
trypsin digestion was carried out by adding trypsin to the 
extract. Incubation occurred at 37 °C for 24 h or 48 h.
Results: Reproducibility of the reflectance signal was good 
(within-run imprecision: 6.1%; between-run imprecision: 
6.2%). Results were linear in the range 103–106 WBC/100 mg 
faeces. The lower limit of detection was 4 WBC/μL and 
the lower limit of quantification was 5 WBC/μL. Stabil-
ity of LE activity in stool and faecal matrix was good. An 
adequate correlation was obtained between leukocyte 
esterase activity and the faecal calprotectin concentration: 
log(y) = 4.28+0.29log(x). In vitro experiments monitored 
the digestion of leukocyte esterase and faecal calprotectin. 
Leukocyte esterase activity was significantly less affected 
by trypsin activity than calprotectin immunoreactivity.
Conclusions: Quantitative leukocyte esterase activity of 
faecal extracts provides information about the leukocyte 
count in the gut lumen. Leukocyte esterase is a promis-
ing and affordable alternative biomarker for monitoring 
inflammatory bowel disease.
Keywords: calprotectin; faeces; inflammatory bowel 
disease; leukocyte esterase; trypsin.
Introduction
Crohn’s disease (CD) and ulcerative colitis, collectively 
known as inflammatory bowel disease (IBD), are chronic 
illnesses of the gastrointestinal tract characterised by a 
recruitment of leukocytes in the intestinal wall [1, 2]. In 
IBD, activated leukocytes (mostly polymorphonuclear 
cells) infiltrate the mucosa and appear in faeces due to 
shedding in the intestinal lumen [3, 4]. Faeces is in direct 
contact with this inflammed intestinal mucosa, thus 
making stool is an obvious place for biomarker discovery 
in IBD [5]. High faecal neutrophil levels have been detected 
in IBD and may be used as markers of disease activity [6, 7].
At the time being, the two most commonly used faecal 
biomarkers for IBD are calprotectin and lactoferrin [8]. 
Calprotectin is a 36  kDa protein, accounting for 60% of 
soluble proteins in the cytosol of neutrophils. Calprotectin 
is a marker of local inflammation in which the concentra-
tion reflects the neutrophil cell infiltrate in the intestinal 
mucosa [9, 10]. An increased value of faecal calprotectin 
leads to the identification of patients with suspicion of IBD 
and in need of an endoscopy [9, 11]. Lactoferrin is an iron-
binding glycoprotein expressed by activated neutrophils. 
It is released by the injured tissue during inflammation. 
Other faecal neutrophil-derived proteins (e.g., lysozyme, 
myeloperoxidase, granulocyte elastase, S100A12) have 
been investigated in IBD with less success [8]. Calprotectin, 
lactoferrin and other proteins are produced in significant 
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amounts by inflammatory cells and these biomarkers cor-
relate well with colorectal and intestinal inflammation [12, 
13]. The faecal excretion of Indium 111-labelled leukocytes 
is still the golden standard faecal marker of inflammation. 
Unfortunately, neutrophil counting in faecal specimens is 
hampered by pre-analytical issues: the sample should be 
examined within a few hours of its collection [7].
Leukocyte esterases (LE) are cytoplasmatic enzymes 
present in polymorphonuclear cells. LE activity has been 
used for decades to detect the presence of white blood 
cells (WBC) in human body fluids (e.g., urine, perito-
neal fluid). These esterases cleave a derivatised pyrazole 
amino acid ester to liberate derivatised hydroxy pyrazole. 
This pyrazole can react with a diazonium salt to produce 
a purple colour, which allows a simple and affordable 
quantification [14]. In 1993, Brouwer proposed semiquan-
titative LE analysis of faecal extracts for the monitoring of 
IBD. A strong correlation between faecal lysozyme con-
centrations and faecal LE activity was found [15]. Modern 
automated urine test strip analysers offer the possibility 
to obtain reflectance readings meaning that test results 
no longer need to be expressed semiquantitatively in 
an ordinal scale. The reflectance value (%) is inversely 
related to the concentration of the analyte in the sample. 
Access to the instrument’s raw data theoretically allows a 
higher analytical sensitivity and a better precision, as also 
shown by Penders et al. [16].
Trypsin (EC 3.4.21.4) is an endopeptidase produced in 
abundant amounts by the human pancreas and found in 
the intestinal lumen where it hydrolyses several proteins. 
Following release of trypsinogen, the enzyme reaches its 
highest activity in the proximal part of the duodenum. 
During transit, activity of proteases decreases [17, 18]. As 
calprotectin contains 14 residues which may act as poten-
tial cleavage sites for trypsin, (partial) digestion of calpro-
tectin by trypsin can be postulated [19]. Digestion of LE by 
trypsin has not yet been described.
In this study, we first wanted to explore the possibili-
ties of faecal LE activity as a alternative biomarker for IBD, 
which is of major clinical importance. Additionally, we 
wanted to evaluate the proteolytic effect of trypsin on the 
faecal LE concentration.
Materials and methods
Extract preparation
Faecal extracts were prepared with the faecal sample prepara-
tion kit (Roche diagnostics, Mannheim, Germany) according to the 
manufacturer’s instruction. After adding a standardised amount of 
faeces (100 mg) to a tube, 5 mL of EliA Calprotectin Extraction Buffer 
(Thermo Scientific, Uppsala, Sweden) was added and the sample was 
vortexed. After centrifugation (at 1200 g for 10 min) the supernatant 
was used as a faecal extract in our experiments. 107 routine faecal 
samples from outpatients consulting the Department of Gastro-
Enterology were used (some patients provided more than one sample 
with several weeks between every sample). All samples were com-
pletely processed within 2–4 h after arrival. The use of these samples 
was approved by the Ethical Committee.
Method evaluation
Test strip analysis was carried out using Combur Test M strips on 
the Cobas u 411 analyser (Roche diagnostics, Mannheim, Germany). 
The strips include reagent pads for ordinal scale reporting of rela-
tive density, pH, LE, nitrite, protein, glucose, ketones, urobilinogen, 
bilirubin, and haemoglobin/myoglobin. The intensity of the reaction 
colour of the test pad is detected by measuring the percentage of 
light reflected from the surface of the test pad. The reflectance value, 
expressed as a percentage is inversely related to the concentration of 
the analyte in the sample. The following equation by Penders et al. 
was used to estimate the number of WBC in faecal extract: y = 83.7–
15.4log(x) where y is the reflectance in% an x the number of WBC (106 
cells/L) [16]. First an ideal dilution was chosen for experiments and 
20 μL was pipetted onto the LE reagent pad. Next, within-run impre-
cision, between-run imprecision, linearity, stability, limit of detec-
tion, and limit of quantification were assessed for LE activity in faecal 
extracts. LE activity was compared to the calprotectin levels in the 
faecal extract and regression analysis was performed. Calprotectin 
was measured on the Phadia ImmunoCAP 250 analyser (Thermo Sci-
entific, Uppsala, Sweden) according to the manufacturer’s instruc-
tions. Results were expressed in mg/kg. The limit of detection of the 
method is 15 mg/kg [20].
Proteolysis by trypsin
Trypsin activity was determined using Nα-Benzoyl-L-arginine 
4-nitroanilide hydrochloride (BAPNA, Sigma Aldrich, St. Louis, 
MI, USA) as a substrate for trypsin (Sigma Aldrich) in a colorimet-
ric method. The amount of 4-nitroaniline formed was subsequently 
measured by the increase in absorbance at 405 nm (25 °C). A trietha-
nolamine solution (TEA 0.2 mol/L, Sigma Aldrich; CaCl2 0.02 mol/L, 
Sarstedt, Nümbrecht, Germany) adjusted to pH 7.8 was used as buffer. 
Results were expressed in BAPNA units (U/L). To evaluate the stabil-
ity of LE activity, trypsin digestion was carried out in vitro by adding 
trypsin (Sigma Aldrich) solution (1 mg/mL, 1mM HCl). Incubation 
was performed at 37 °C. Samples were analysed for calprotectin and 
LE activity after 24 h and 48 h of incubation.
Statistics
All calculations were made in Excel 2010 and MedCalc (version 
11.6.1.0, Mariakerke, Belgium). Results were given as median and 
inter-quartile ranges (IQR). Comparisons between conditions were 
made using a Wilcoxon test. A value of p < 0.05 was considered 
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for 24 h. A mean decline of 1.52% was seen after 24 h. 
Next, four stool samples were extracted again after 24 h 
while kept at 4 °C, a difference of respectively 1.6%, 3.3%, 
0.0% and 0.9% was seen. As mentioned above, LE activity 
between-run imprecision was evaluated over 15 different 
days. These 15 aliquots were frozen at −20 °C and between-
run imprecision is therefore a measurement for stability 
at −20 °C.
Next, in our method evaluation we compared faecal 
calprotectin values and LE activity for 107 samples. After 
excluding samples with values below 15 mg/kg (limit of 
quantification for calprotectin), regression analysis was 
performed for 46 samples. A fair agreement was obtained 
between LE activity and faecal calprotectin concentration: 
log(y) = 4.28+0.29log(x) with a correlation coefficient (r) of 
0.27. LE activity is expressed as the number of white blood 
cells in 100 mg/faeces [16]. Figure 2 depicts the correla-
tion between LE activity and calprotectin concentration in 
faecal extracts. The arrow shows a case where proximal 
lesions were confirmed by endoscopy.
Proteolysis by trypsin
In vitro-experiments monitored the digestion of LE and 
faecal calprotectin in 10 samples. The same conditions as 
in our previous publication were used [19]. After adding 
500 μL of trypsin solution (1 mg/mL) to 500 μL 1:100 
diluted calprotectin in faecal matrix, proteolysis was 
monitored for 24  h and 48 h. The median trypsin activ-
ity after adding trypsin was 57.3 U/L (IQR: 55.9–65.9 U/L). 
statistically significant. Regression analysis was performed. The 
lower limit of detection was calculated as the mean value plus 3 
standard deviations (SD) for a blank sample. The lower limit of quan-
tification was calculated as the mean value plus 6 SD for a blank 
sample.
Results
Method evaluation
Pilot experiments showed that a 1:10 dilution of faecal 
extract (prepared according to the manufacturer’s instruc-
tion) in saline was ideal for test strip analysis and for 
reflectance readings. 20 μL was pipetted onto the reagent 
pad for reflectance measurements. Reproducibility of 
the reflectance signal was good for LE activity in faecal 
extract. A within-run imprecision of 6.1% was calculated 
after analysing a routine sample 15 times. Consequently, 
a between-run imprecision of 6.2% was calculated after 
analysing the same sample on 15 different days. The 
sample contained a mean number of white blood cells 
of 47 × 103/100 mg faeces. Results were linear in the range 
103–106 WBC/100 mg faeces (corresponding to faecal cal-
protectin concentration ranges from ±1 to ±1000 mg/kg). 
Results are shown in Figure 1. Calprotectin levels shown 
are theoretically as a serial dilution was performed. The 
lower limit of detection for leukocytes was 4 WBC/μL and 
the lower limit of quantification was 5 WBC/μL (respec-
tively corresponding to 2019 en 2688 WBC/100 mg faeces). 
Data of the method evaluation are summarised in Table 1. 
To evaluate the stability of LE activity, 14 samples were pro-
cessed and faecal matrix was placed at room temperature 
Figure 1: Linearity between calprotectin levels (x, mg/kg) and 
leukocyte esterase (LE) activity expressed as the number of white 
blood cells in 100 mg faeces (y, WBC/100 mg faeces).
Results were linear in the range 103–106 WBC/100 mg faeces (cor-
responding to calprotectin concentration ranges from ±1 to ±1000 
mg/kg). WBC, white blood cells.
Table 1: Method evaluation of leukocyte esterase (LE) activity in 
faecal extracts. Within-run imprecision (Cwr), between-run impreci-
sion (Cbr), limit of detection (LOD), limit of quantification (LOQ) were 
assessed. Regression analysis was performed for LE activity (y) and 
calprotectin levels (x) in faecal extracts for 46 samples out of 107.
Performance characteristics 
of LE activity in faecal extracts
  Results
Cwr   6.1%
Cbr   6.2%
LOD   4 WBC/μL
2019 WBC/100 mg faeces
LOQ   5 WBC/μL
2688 WBC/100 mg faeces
Linearity   103–106 WBC/100 mg faeces
Regression analysis   log(y) = 4.28+0.29log(x)
r = 0.27
Cwr, within-run imprecision; Cbr, between-run imprecision; LE, leuko-
cyte esterase; LOD, limit of detection; LOQ, limit of quantification; 
r, correlation coefficient; WBC, white blood cells.
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Analogue findings for calprotectin levels were found, 
trypsin digestion leaded to loss of immunoreactivity and 
analyte stability. A median relative decrease of 59.0% 
(IQR: 37.3%–74.3%) was seen after 24 h of incubation, and 
a median absolute decrease of 63.5% (IQR: 32.8%–77.3%) 
after 48  h of incubation. Nevertheless LE activity was 
less affected by trypsin activity than calprotectin immu-
noreactivity. After trypsin treatment, a median relative 
decrease of 26.5% (IQR: 13.5%–31.3%) was seen after 24 h 
of incubation, and a median absolute decrease of 28.5% 
(IQR: 12.8%–32.5%) after 48 h of incubation. Differences 
between decreases of LE activity and calprotectin levels 
after 24  h and 48  h of incubation were evaluated using 
a Wilcoxon test. Decreases were statistically significant 
after 24 h and 48 h of incubation (for both p = 0.01). Results 
are shown in Figure 3.
Discussion
Analysis of the test strip reflectance data allows a quan-
tification of the analyte over a wide activity range. Using 
a hyperbolic calibration curve, reflectance data can be 
converted into quantitative WBC counts [16]. As urine test 
strips are inexpensive, as compared to immunochemi-
cal calprotectin testing, this could improve screening for 
IBD. It offers an improved, fast, reliable method that is 
easy to handle and usable in primary care laboratories. 
In our study, LE activity could be quantified in routine 
faecal extracts. Reproducibility of the obtained results 
was good (both within- and between-run imprecision 
were below 10%), which is guaranteed by the constant 
Figure 3: Distribution of relative decreases of leukocyte esterase 
(LE) activity and calprotectin after adding a median trypsin concen-
tration of 57.3 U/L (IQR: 55.9–65.9 U/L) (n = 10) and incubation for 
24 h (A) or 48 h (B) at 37 °C.
Differences are expressed as compared to the baseline reflectance 
levels (baseline = before adding trypsin). A statistically significant 
difference between LE activity and faecal calprotectin was found 
(p = 0.01). h, hours; LE, leukocyte esterase activity.
Figure 2: Regression analysis between calprotectin levels (x, mg/
kg) and leukocyte esterase (LE) activity expressed as the number of 
white blood cells in 100 mg faeces (y, WBC/100 mg faeces).
The following regression equation was obtained: 
log(y) = 4.28+0.29log(x) (r = 0.27). The arrow depicts a confirmed 
case of IBD with proximal lesions. WBC, white blood cells.
reaction temperature. Furthermore, the buffered extrac-
tion medium used for sample preparation adds to create 
an optimal environment for measuring the enzyme activ-
ity. As a result of the procedure for applying the faecal 
extract to the test pads on the reflectance reader, improper 
dipping is not a problem, neither is confusion about 
sample contamination caused by dipping the strip in the 
tube, which potentially leads to interferences.
When faecal extracts were subjected to trypsin deg-
radation for prolonged incubation times (24–48 h) at 
37 °C, LE proved to be more resistant against proteolysis 
than calprotectin. Human calprotectin shows 14 poten-
tial cleavages sites for trypsin and previous experiments 
showed a statistically significant breakdown of calpro-
tectin [19]. As trypsin shows a limited stability, our find-
ings do not imply major pre-analytical precautions for LE 
or calprotectin following sampling [21]. These results are 
in agreement with earlier data where the half-life of LE in 
faecal extracts was measured to be 2–3 days. In contrast, 
the half-life of lysozyme in faecal extracts varied between 
0.5 h and 3.2 h [15].
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In this study, we further compared the LE activity 
quantitatively assayed on the Cobas u 411 automated strip 
reader with the calprotectin levels to evaluate the possi-
ble diagnostic value of faecal LE. As expected, calprotec-
tin and LE showed an adequate correlation, as they are 
both markers of the number of neutrophils which have 
migrated through the mucosal membrane of the gut wall. 
In contrast to WBC count, LE is not affected by subsequent 
cell lyses within the gut lumen. Furthermore, dilution 
experiments of faecal extracts demonstrated that LE was 
a more sensitive biomarker than calprotectin. Test strip 
measurements had excellent lower limits of detection 
and quantification. Results were also linear in the range 
103–106 WBC/100 mg faeces (corresponding to faecal cal-
protectin concentration ranges from ±1 to ±1000 mg/kg). 
In a previous study correlating test strip data with urinary 
flow results, r was −0.69 between the flow cytometric WBC 
count and the LE reaction. The presence of esterase inhibi-
tors in faeces and increased protein concentrations might 
negatively affect test results for LE [22].
The turnaround time for LE was short enough (2–4 h) 
not to affect the readings [23]. It is known that time inter-
vals can influence results of automated test strip analy-
sis, especially for leukocyte ratings. Froom et  al. found 
that that urine testing for red and white blood cells with 
a dipstick is precise but unstable if testing is delayed for 
24 h [24]. As the technique is not time-consuming and well 
known in the laboratory, the preparation of faecal matrix 
is only a minor addition to the workload. When samples 
cannot be analysed immediately, aliquots of faecal matrix 
can be placed at room temperature. Evaluation of stability 
showed that LE activity remains stable when faecal matrix 
is stored at room temperature (mean decline of 1.52%) 
or at −20 °C (between-run imprecision of 6.2%). Prelimi-
nary data showed that LE activity remains stable during 
24 h when stool is kept at 4 °C. This may be an important 
feature, as samples are not always brought immediately to 
the laboratory.
Interpretation of calprotectin values in proximal 
bowel disease is proven to be difficult [25, 26]. Siponnen 
et  al. showed a low sensitivity for calprotectin in small 
bowel CD. Despite active CD in the small bowel, faecal 
calprotectin values were low [27]. Possible explanations 
could be the proteolytic effect of the large amounts of 
trypsin released by the pancreas into the lumen of the 
duodenum [19]. As our experiments show that LE activ-
ity is less influenced by trypsin, it could be an alternative 
biomarker. Also in patients with cystic fibrosis (CF) where 
faecal calprotectin values are higher, possibly explained 
by pancreatic insufficiency, LE activity could be a valu-
able alternative [28]. The correlation coefficient found is 
rather low, which can be explained by the fact that low 
faecal calprotectin levels can correlate with high levels of 
LE activity, when proximal lesions are present. The arrow 
in Figure 2 depicts such a patient, where proximal lesions 
were confirmed by endoscopy. Summarised, LE activity 
cannot simply replace calprotectin, further prospective 
studies will be needed to assess sensitivity and specificity 
of the test.
In conclusion, quantitative test strip analysis pro-
vides reliable data on faecal WBC counts. LE reflectance 
data are promising for monitoring IBD. The faecal esterase 
allows non-invasive assessment of the intestinal inflam-
mation. In comparison with immunochemical assays of 
specific leukocyte proteins, the LE test is about two orders 
of magnitude cheaper. The required technology needed 
for quantification is within reach of present day point of 
care testing. Further clinical studies will be required to 
define the exact role of faecal LE and the specific clinical 
applications in different settings of IBD patients and other 
patient populations. Potential clinical applications might 
be patients with proximal bowel disease, detecting active 
IBD, predicting recurrence of disease after surgery or mon-
itoring the effects of medical therapy [8].
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